Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis.
Siafis S, Wu H, Wang D, Burschinski A, Nomura N, Takeuchi H, Schneider-Thoma J, Davis JM, Leucht S.
Mol Psychiatry. 2023 Aug;28(8):3267-3277. doi: 10.1038/s41380-023-02203-y. Epub 2023 Aug 3.
A rating scale for extrapyramidal side effects.
Simpson GM, Angus JW.
Acta Psychiatr Scand Suppl. 1970;212:11-9. doi: 10.1111/j.1600-0447.1970.tb02066.x.
Trihexyphenidyl dependence.
McInnis M, Petursson H.
Acta Psychiatr Scand. 1984 Jun;69(6):538-42. doi: 10.1111/j.1600-0447.1984.tb02528.x.
Antidopaminergic medications in Huntington's disease.
Tan AM, Geva M, Goldberg YP, Schuring H, Sanson BJ, Rosser A, Raymond L, Reilmann R, Hayden MR, Anderson K.
J Huntingtons Dis. 2025 Feb;14(1):16-29. doi: 10.1177/18796397241304312. Epub 2025 Jan 12.
[Treatment-resistant schizophrenia].
Yahyaten OB.
Rev Med Brux. 2014 May-Jun;35(3):169-73.
Olanzapine for schizophrenia.
Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S.
Cochrane Database Syst Rev. 2003;(1):CD001359. doi: 10.1002/14651858.CD001359.
Olanzapine for schizophrenia.
Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S.
Cochrane Database Syst Rev. 2000;(2):CD001359. doi: 10.1002/14651858.CD001359.
Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia.
Jung HY, Kim JH, Ahn YM, Kim SC, Hwang SS, Kim YS.
Hum Psychopharmacol. 2005 Jan;20(1):41-5. doi: 10.1002/hup.655.
Rating scales to measure side effects of antipsychotic medication: A systematic review.
van Strien AM, Keijsers CJ, Derijks HJ, van Marum RJ.
J Psychopharmacol. 2015 Aug;29(8):857-66. doi: 10.1177/0269881115593893. Epub 2015 Jul 8.
Trimipramine--an atypical neuroleptic?
Eikmeier G, Berger M, Lodemann E, Muszynski K, Kaumeier S, Gastpar M.
Int Clin Psychopharmacol. 1991 Winter;6(3):147-53. doi: 10.1097/00004850-199100630-00003.
